Thomas Hoehler

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Different Transcriptional Activity and In Vitro TNF-α Production in Psoriasis Patients Carrying the TNF-α 238A Promoter Polymorphism

W. Kaluza, Esther Reuss, Sabine Grossmann et al. · Journal of Investigative Dermatology · 2000 · 224 citations · Full text

Inflammation, Vitro Tnf-α Production, Transcriptional Regulation +8

Apparent minimum free energy requirements for methanogenic Archaea and sulfate-reducing bacteria in an anoxic marine sediment

Thomas Hoehler · FEMS Microbiology Ecology · 2001 · 158 citations

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

Stefan Boeck, Thomas Hoehler, G. Seipelt et al. · Annals of Oncology · 2007 · 77 citations

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +8

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

Markus Moehler, Stephan Kanzler, Jochen Raedle et al. · Annals of Oncology · 2009 · 53 citations · Full text

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +8